Next Article in Journal
Preferential and Increased Uptake of Hydroxyl-Terminated PAMAM Dendrimers by Activated Microglia in Rabbit Brain Mixed Glial Culture
Next Article in Special Issue
Synthesis of 8-Fluoro-3,4-dihydroisoquinoline and Its Transformation to 1,8-Disubstituted Tetrahydroisoquinolines
Previous Article in Journal
Synthesis and Antibacterial Activity of New Thiazolidine-2,4-dione-Based Chlorophenylthiosemicarbazone Hybrids
Previous Article in Special Issue
Synthesis of Some Novel Fused Pyrimido[4″,5″:5′,6′]-[1,2,4]triazino[3′,4′:3,4] [1,2,4]triazino[5,6-b]indoles with Expected Anticancer Activity
 
 
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Synthesis and Pharmacological Studies of Unprecedented Fused Pyridazino[3′,4′:5,6][1,2,4]triazino[3,4-b][1,3,4]thiadiazine Derivatives

1
Department of Chemistry, Faculty of Science, Taif University, Taif 21974, Saudi Arabia
2
Department of Basic Science, Faculty of Industrial Education, Helwan University, Cairo 11795, Egypt
3
Department of Chemistry, Faculty of Science, Zagazig University, Zagazig 44511, Egypt
*
Author to whom correspondence should be addressed.
Submission received: 22 March 2018 / Revised: 23 April 2018 / Accepted: 23 April 2018 / Published: 27 April 2018
(This article belongs to the Collection Heterocyclic Compounds)

Abstract

:
A novel fused system with three or four fused rings—pyridazino[3′,4′:5,6][1,2,4]triazino[4,3-b][1,2,4,5]tetrazine and pyridazino[3′,4′:5,6][1,2,4]triazino[3,4-b]pyrimido[4,5-e][1,3,4]thiadiazine was obtained from the starting materials 4(6H)-amino-3-hydrazino-7-(2-thienyl)pyridazino[3,4-e][1,2,4]-triazine 2 and 9-amino-3-(2-thienyl)-2H,8H-pyridazino[3′,4′:5,6][1,2,4]triazino[3,4-b][1,3,4]thiadiazine-8-carbonitrile 12. Each of the starting compounds was subjected to a number of cyclization reactions to obtain a series of new heterocyclic fused systems, 310 and 1323, via bifunctional reagents. Some of the synthesized compounds were screened against three cell lines including HepG2, HCT-116 and MCF-7 to discover their anticancer activity. The synthesized compounds were characterized depending on their elemental analyses and spectral data.

1. Introduction

As the world’s population increases, so too does the number of health problems, and the need to discover new therapeutics becomes even more urgent. Drug design represents the greatest hope for success in the present and future era. Discovering new drugs means saving the lives of many people. Heterocyclic compounds are widely distributed everywhere and area mainstay for life. Now, a vast number of heterocyclic compounds are pharmacologically active and are actually in clinical use [1]. To make scientific progress in the field of drug discovery, our main goal was to discover new drug classes with much better therapeutic profiles. In this paper, we synthesized two novel heterocyclic fused systems containing mainly thiophene as a substituent in pyridazinotriazine, which fused with tetrazine, thiadiazine, pyridine, and pyrimidine, rings in one way or another.
Thiophene and its derivatives have been widely distributed in many naturally occurring compounds and are employed to address different health hazards. They are responsible for various biological activities such as anti-inflammatory [2], antipyretic [3], anti-hypotensive [4], anti-convulsant [5], anti-viral [6], antitumor [7], fungicidal [8], herbicidal [9], anti-microbial [10] activities, and act as a plant-growth regulator [11]. Some of the thiophene derivatives exhibited divergences in anti-diabetic and anti-inflammatory activities [12].
Among a wide variety of 1,2,4-triazines screened for anticancer activities, a variety of fused 1,2,4-triazines have been reported to be extremely potent. Several heterobicyclic systems containing the 1,2,4-triazine ring have shown important biological activities. The imidazo[2,1-c][1,2,4]triazin-4(6H)-one core system showed noticeably lower cytotoxicity towards normal cells and several-times higher cytotoxicityagainst cancer cell lines [13,14,15,16,17]. Additionally, numerous heterobicyclic systems bearing the 1,2,4-triazine moiety possess lung, leukemia, CNS, and breast anticancer activities [18,19,20]. Pyrazolo[5,1-c][1,2,4]benzotriazine derivatives showed selective cytotoxicity on the human colorectal adenocarcinoma cell line HCT-8 in hypoxic conditions as well as normoxic conditions [21,22]. Several fused 1,2,4-trizines showed inhibitory activities on CYP1A1 [23].
In addition, a 1,2,4-triazine ring condensed with pyrimidine acts as an inhibitor of chaperone Heat-shock protein 90 (Hsp90) and, therefore, a potential anticancer agent [24]. Among fused 1,2,4-triazines, 8-(2-methoxyphenyl)-3,4-dioxo-6-thioxo-3,4,6,7-tetrahydro-2H-pyrimido[6,1-c][1,2,4] triazine-9-carbonitrile induced a significant growth inhibition of liver cancer cells HEPG2, which resulted to be equally as powerful as Doxorubicin and more potent than 5-fluorouracil used as reference drugs [25,26]. Other pyridotriazines were described as inhibitors of cyclin-dependent kinase or tyrosine kinase enzymes [27]. Substituted pyrimido[5,4-e][1,2,4]triazine-5,7(1H,6H)diones and pyrimido[5,4-e][1,2,4]triazine-5,7(6H,8H)diones were found active in antagonizing the b-catenin/TCF complex [28], which represents a useful tool for the treatment of cell proliferative disorders such as colorectal cancers. The 3-(4-(2-(Diethylamino)ethoxy)phenyl)-1,6-dimethylpyrimido[5,4-e][1,2,4]triazine-5,7(1H,6H)-dione showed the highest activity with an IC50 of 0.016 mM, the best LD50/IC50 ratio (8.32), and a favorable pharmacokinetic profile [28]. Recently, compound 2-(p-nitrobenzylidene)-4-phenyl-thioxo-triazino[2,1-a]-1,2,4-triazine-1,7-dione showed high activity against the HepG-2 cell line, showing an IC50 of 2.67 mM [29].

2. Results and Discussion

Once in a while, we look for unprecedented fused systems. Our challenge this time is to use the previously prepared compounds 1 and 11 [30,31] as a kernel for constructing a new fused system through subsequent reactions with a bifunctional reagent.
The simple molecule 4-amino-3-mercapto-6-[2-(2-thienyl)vinyl]-1,2,4-triazin-5(4H)-one 1 reacted with hydrazine hydrate in refluxed ethanol to give the starting compound 4(6H)-amino-3-hydrazino-7-(2-thienyl)pyridazino[3,4-e][1,2,4]triazine 2. This compound showed in its 1H-NMR the disappearance of each SH group and the two olefinic protons of the side chain double bond in compound 1 and its IR supported the observations where the amide carbonyl also disappeared. These observations led to the conclusion that the hydrazine hydrate cyclizes the side chain double bond with the carbonyl group to give the pyridazine ring along with the substitution of the SH group with the hydrazine group (Scheme 1). Compound 2 reacted with carbon disulphide either on alcoholic KOH and/or pyridine to give the new target heterocylic fused system known as pyridazino[3′,4′:5,6][1,2,4]triazino[4,3-b][1,2,4,5]tetrazine-9(10H)-thione derivative 3. The same was obtained when compound 2 reacted with triethyl orthoformate, thiourea, formamide, acetic formic anhydride, and sebacoyl chloride. Reaction of 2 with triethyl orthoformate in boiling DMF gave 9-ethoxy-3-(2-thienyl)-7,8,9,10-tetrahydro-2H-pyridazino[3′,4′:5,6][1,2,4]triazino[4,3-b][1,2,4,5]tetrazine 4. In addition, the reaction of compound 2 with malononitrile in basic medium yielded 8-Amino-3-(2-thienyl)pyrazolo[5,1-c]pyridazino[3,4-e][1,2,4]triazine-7-carbonitrile 5 through the nucleophilic substitution of the hydrazino group followed by cyclization and in situ auto-oxidation for aromatization of the diazole ring; reaction with thiourea in boiling acetic acid yielded 9-amino-3-(2-thienyl)-7,10-dihydro-2H-pyridazino[3′,4′:5,6][1,2,4]triazino[4,3-b][1,2,4,5]tetrazine 6 (Scheme 1). The structure’s characterization of the yielded compounds was based on their spectral data and the elemental analysis. Compound 3 in its mass spectra molecular ion peak M+ at 304 (22.1) and its IR showed a + signals due to the formation of a cyanodiazole ring. On the other hand, the structure of 9-aminotetrazino derivative 6 was confirmed from its 1H-NMR where it showed a signal due to NH2 and 3 NH groups at δ = 5.68, 9.82, 11.37 and 13.05 ppm, respectively.
The reaction of compound 2 with thioglycolic acid in boiling ethanol yielded 7-amino-3-(2-thienyl)-2,7,9,10-tetrahydro-8H-pyridazino[3,4-e][1,2,4]triazino[3,2-c][1,2,4]triazin-8-one 7 while, with formamide in refluxing, DMF gave 3-(2-thienyl)-7,8-dihydro-2H-pyridazino[3′,4′:5,6][1,2,4]triazino[4,3-b][1,2,4,5]tetrazine 8 (Scheme 2). The structures of compounds 7 and 8 were confirmed from their 1H-NMR and IR where the IR of compound 7 showed a band due to an amide carbonyl at 1654 cm1 and no evidence supported the presence of S atom functional groups such as SH or C=S and this means that the reaction was carried out through the nucleophilic substitution on thioglycolic acid CH2 followed by cyclization to give the triazinone ring. The 1H-NMR supported this elucidation by the appearance of doublets due to the electronic environment unsymmetrical CH2 signal at δ = 3.65, 3.89 ppm. The 1H-NMR of compound 8 showed no NH2 group signals and its 13C-NMR showed an extra signal due to a carbon atom for the formed tetrazine ring.
The 3-(2-thienyl)-7,8,9,10-tetrahydro-2H-pyridazino[3′,4′:5,6][1,2,4]triazino[4,3-b][1,2,4,5]-tetrazine 9 was prepared by the reaction of compound 2 with acetic formic anhydride [32] in boiling ethanol while the dimmer 10 was formed from the reaction of 2 with sebacoyl chloride in basic conditions (Scheme 2). The structures of compounds 9 and 10 confirmed from their spectral date where the two compounds showed the disappearance of the two NH2 groups of compound 2 in both IR and 1H-NMR. The 13C-NMR supported this conclusion by showing signals due to sp3 carbons in the range δ = 23.68–55.29 ppm.
Compound 12 was prepared by reaction of compound 11 [31] with hydrazine hydrate to give the new hetrocylic system pyridazino[3′,4′:5,6][1,2,4]triazino[3,4-b][1,3,4]-thiadiazine, which is an unprecedented system. Compound 12 acts as a starting material in some cyclization reactions where it reacted with cyanamine in an EtOH/H2O mixture (4:1 by volume) to give the guanidine derivative 13. The idea of cyclization of compound 13 was intuitive from the appearance of two spots in TLC during compound 13 synthesis. Therefore, we thought to repeat the synthesis of compound 13 but with a longer time reflux. This reaction resulted in [7,7-diamino-3-(2-thienyl)-7,8-dihydro-2H-pyridazino-[3,4-e][1,2,4]triazino[6,1-c][1,2,4]triazin-9-yl](thioxo)acetonitrile 15. Compound 14 was formed by treating compound 12 with urea and/or thiourea in boiling acetic acid (Scheme 3). Compound 12 showed in its IR the disappearance of the amide carbonyl to confirm the formation of the pyridazine ring. The structure of compound 13 was recognized from its 1H-NMR where it showed three NH signals instead of one in compound 12. The structure of compound 14 was proven by the disappearance of the CN group in its IR chart with the appearance of another NH2 in both IR and 1H-NMR. The mechanism describes the cyclization of compound 13 shown in Scheme 4 [31]. The structure of compound 15 showed an absorption band at 1345 cm−1 due to C=S with other bands at 3376–3212 cm−1 and 2207 cm−1 due to the 2NH2 and CN groups, respectively.
The [8-cyano-3-(2-thienyl)-2H,8H-pyridazino[3′,4′:5,6][1,2,4]triazino[3,4-b][1,3,4]thiadiazin-9-yl]carbamodithioic acid 16, formed from the reaction of compound 12 with carbon disulphide in alcoholic KOH, was cyclized to 3-(2-thienyl)-2H,7aH-pyridazino[3′,4′:5,6][1,2,4]triazino[3,4-b]pyrimido[4,5-e]-[1,3,4]thiadiazine-8,10(9H,11H)dithione 17 either by the long boiling for compound 16 in ethanol or by direct reaction of compound 12 with CS2 in pyridine (Scheme 5).
Formamide with compound 12 in boiling DMF gave 8-amino-3-(2-Thienyl)-2H,7aH-pyridazino[3′,4′:5,6][1,2,4]triazino[3,4-b]pyrimido-[4,5-e][1,3,4]thiadiazine 18 while with triethyl orthoformate in DMF it yielded ethyl [8-cyano-3-(2-thienyl)-2H,8H-pyridazino[3′,4′:5,6][1,2,4]triazino[3,4-b][1,3,4]-thiadiazin-9-yl]imidoformate 19, which on reaction with hydrazine hydrate in boiling EtOH gave 9-amino-8-imino-3-(2-thienyl)-7a,8-dihydro-2H,9H-pyridazino[3′,4′:5,6][1,2,4]-triazino[3,4-b]pyrimido[4,5-e]-[1,3,4]thiadiazine 20 (Scheme 5).
To confirm the above structures, we scrutinized their IR, 1H-NMR, and 13C-NMR. The IR of compound 16 showed a new band at 2613 and 1345 cm−1 due to SH and C=S groups with the disappearance of the NH2 group of compound 12.Additionally, its 1H-NMR showed the most important signal at δ = 13.78 ppm, corresponding to the SH group. In the case of compound 17, the groups that underpin the structure of compound 16 vanished and new groups characteristic of the compound 17 structure appeared. The 1H-NMR of 17 showed the demise of the SH group and a third NH group appeared. The IR of compound 18 showed the disappearance of the CN group, which contributes to the cyclization process. The 1H-NMR of 19 illustrates a doublet and triplet at δ = 1.20 and 3.33 due to CH3 and CH2, respectively. Additionally, 13C-NMR supported this evidence; it showed signals due to CH3 and CH2 at δ = 13.7 and 62.59 ppm, which disappeared in compound 20 1H-NMR.
The postulated mechanism illustrates the cyclization of compound 17 shown in Scheme 6.
The 8,10-diamino-3-(2-thienyl)-2H,7aH-pyridazino[3′,4′:5,6][1,2,4]triazino[3,4-b]pyrido[2,3-e][1,3,4]thiadiazine-9-carbonitrile 21 resulted from the reaction of compound 12 with malononitrile in basic conditions. The reaction of compound 12 with ethyl cycnoacetate yielded two different compounds, 22 and 23, according to the condition of the reaction. In addition, boiling of compound 12 with acetic anhydride yielded N-[8-cyano-3-(2-thienyl)-2H,8H-pyridazino[3′,4′:5,6][1,2,4]triazino[3,4-b][1,3,4]-thiadiazin-9-yl]acetamide 24 (Scheme 7). The structure of compound 21 was elucidated from 1H-NMR to 13C-NMR where the 1H-NMR showed two amino groups at δ = 6.02 and 6.59 ppm while 13C-NMR showed an extra three carbons more than compound 12 due to the pyridine ring formed.
The structure formed from the reaction of ethyl cyanoacetate in basic conditions, 8-amino-10-oxo-3-(2-thienyl)-10,11-dihydro-2H,7aH-pyridazino[3′,4′:5,6][1,2,4]-triazino[3,4-b]pyrido[2,3-e][1,3,4]thiadiazine-9-carbonitrile 22, was confirmed from the compound IR where it showed an amide carbonyl and its 1H-NMR showed no methylene group like that found in compound 23, which resulted from the reaction of compound 12 with boiling ethyl cyanoacetate. The mechanisms describe the formation of compounds 22 and 23, which are shown in Scheme 8 and Scheme 9, respectively.

Cytotoxic Activity

The in vitro growth inhibitory activity of the synthesized compounds was investigated in comparison with the well-known anticancer standard drugs (cisplatin) under the same conditions using colorimetric MTT assay. Data generated were used to plot a dose–response curve of which the concentration of test compounds required to kill 50% of cell population (IC50) was determined (see Figure 1 and Table 1). The results revealed that all the tested compounds showed inhibitory activity with the tumor cell lines in a concentration-dependent manner. Cytotoxic activity was expressed as the mean IC50 of three independent experiments.
The order of activity against the breast carcinoma cell line (MCF-7) was 16, 2, 12, 3, 4, 7, 6, 5 and 10, with IC50 values of 29.2 ± 0.7, 29.6 ± 0.9, 43.9 ± 1.2, 54 ± 0.8, 54.5 ± 1.2, 78.2 ± 1.2, 100 ± 0.9, 145 ± 3.4, 168 ± 4.5 and 404 ± 3.4 μg/mL, respectively.
The order of activity against the liver carcinoma cell line (HepG2) was 16, 2, 12, 4, 6, 7, 3, 5 and 10 with IC50 values of 23.6 ± 0.6, 25 ± 0.4, 28.6 ± 0.9, 30.2 ± 0.4, 30.7 ± 0.7, 35.6 ± 0.9, 35.5 ± 1.2, 98.1 ± 0.7, 102 ± 0.9 and 206 ± 2.3 μg/mL, respectively.
The order of activity against the colon carcinoma cell line (HCT-116) was 16, 2, 12, 4, 3, 6, 7, 5 and 10 with IC50 values of 27.4 ± 0.6, 30.9 ± 0.4, 34.9 ± 0.6, 45.4 ± 0.8, 46.2 ± 0.7, 59.3 ± 0.8, 59.5 ± 1.2, 160 ± 2.3, 198 ± 2.4 and 244 ± 3.9 μg/mL, respectively.
In conclusion, the results showed that compounds 16, 2 and 12 were the most active against the three tested carcinoma cell lines (HepG2, MCF-7 and HCT-116) compared with cisplatin reference drugs.
Moreover, the compounds 5 and 10 were relatively less active against the tested tumor cell line.

3. Materials and Methods

3.1. General Information

All chemicals were purchased from Sigma (New York, NY, USA). The melting points were measured by a digital Electro thermal IA 9100 Series and were uncorrected. IR spectra were recorded on an ATRAlpha FTIR spectrophotometer (Billerica, MA, USA) from 400 cm−1 to 4000 cm−1. 1H-NMR and 13C-NMR spectra were recorded on a Brüker AC-600 MHz instrument (Bruker, Billerica, Massachusetts). Chemical shifts were expressed as ppm relative to TMS as an internal standard and DMSO-d6 was used as the solvent. Mass spectra were recorded on a Shimadzu GC-MS-QP 1000 EX spectrometer (Shimadzu, Kyoto, Japan). The pharmacological study was carried out at Al-Azhar University (Cairo, Egypt), The Regional Center for Mycology and Biotechnology. Elemental analyses were performed at the Micro-analytical Center, Cairo University (Cairo, Egypt).
4(6H)-amino-3-hydrazino-7-(2-thienyl)pyridazino[3,4-e][1,2,4]triazine2. Hydrazine hydrate (5 mL, excess) was added to a solution of compound 1 [1] (2.52 g, 0.01 mol) in ethanol (20 mL) and the reaction mixture was refluxed for 9 h. The pale yellow precipitate formed after cooling was filtered and crystallized from ethanol to give pale yellow crystals of compound 2. Yield, 89%, m.p.: 284–286 °C. IR: 3371–3193 cm−1 (2NH2 and 2NH) and 1621 cm−1 (C=N). 1H-NMR (DMSO-d6): δ = 5.52 (s, 1H, pyridazine CH), 5.57 (s, 2H, N-NH2), 6.57 (s, 2H, NH-NH2), 7.05 (dd appears t, 1H, J = 7.8, 7.2 Hz, thiophene-HC4), 7.26 (d, 1H, J = 7.8 Hz, thiophene-HC3), 7.58 (d, 1H, J = 10.2 Hz, thiophene-HC5), 7.92 (s, 1H, NH), 8.06 (s, 1H, NH). 13C-NMR (DMSO-d6): δ = 112.5, 118, 120.6, 123.4, 124.6, 141.1, 143.3, 148.0 and 151.8 (Ar-C, C=C, C-S and C=N). Anal. Calcd. for C9H10N8S (262.29): C, 41.21; H, 3.84; N, 42.72; S, 12.22; Found: C, 41.03; H, 3.71; N, 42.59; S, 12.10. LCMS (ESI) m/z (int. %) (263 (2.5)) [M + H]+; Calcd. for (262.29): 262 (11.1), 250 (48.03), 249 (100), 234 (12.68), 219 (12.27), 136 (20.39), 135 (38.11), 121 (11.76), 77 (10.93), 69 (11.81).
3-(2-Thienyl)-7,8-dihydro-2H-pyridazino[3′,4′:5,6][1,2,4]triazino[4,3-b][1,2,4,5]tetrazine-9(10H)-thione3. Method A: A mixture of compound 2 (0.25 g, 0.001 mol) and carbon disulfide (1.5 mL) in ethanolic sodium ethoxide (20 mL, 0.07 g, 0.001 mol) was refluxed for 9 h. The mixture was poured onto ice water after cooling and acidified with HCl. The yellow solid formed was filtered and crystallized from DMF to give compound 3. Yield, 68%, m.p.: over 300 °C. Method B: To a solution of 2 (0.25 g, 0.001 mol) in dry pyridine (15 mL), carbon disulfide (2 mL) was added and the mixture was refluxed for 12 h. After cooling, the solution was poured onto ice water and acidified with HCl. The obtained solid was separated by filtration and crystallized from DMF to give 3. Yield 54%, m.p. over 300 °C. IR: 3271–3232 cm−1 (3NH), 1618 cm−1 (C=N) and 1348 cm−1 (C=S). 1H-NMR (DMSO-d6): δ = 6.70 (s, 1H, pyridazine CH), 7.09 (dd appears t, 1H, J = 9.6, 7.2 Hz, thiophene-HC4), 7.30 (d, 1H, J = 9.6 Hz, thiophene-HC3), 7.51 (d, 1H, J = 10.2 Hz, thiophene-HC5), 9.02 (s, 1H, NH), 11.95 (s, 1H, NH), 12.33 (s, 1H, NH), 12.62 (s, 1H, NH).13C-NMR (DMSO-d6): δ = 111.9, 118.0, 121.3, 127.0, 129.6, 131.6, 136.0, 140.2, 142.6 and 164.0 (Ar-C, C=C, C-S, C=N and C=S). Anal. Calcd. for C10H8N8S2(304.35): C, 39.46; H, 2.65; N, 36.82; S, 21.07; Found: C, 39.41; H, 2.55; N, 36.71; S, 20.95 LCMS (ESI) m/z (int. %) (305 (0.53)) [M + H]+; Calcd. For (304.35): 304 (22.1), 252 (47.06), 251 (44.27), 236 (20.22), 145 (10.20), 136 (18.00), 135 (21.15), 134 (12.64), 121 (28.22), 111 (17.14), 109 (20.35), 98 (19.05), 97 (100), 96 (19.95), 95 (19.11), 85 (29.47), 84 (25.05), 83 (39.25), 71 (50.87), 69 (59.75), 60 (28.03).
9-Ethoxy-3-(2-thienyl)-7,8,9,10-tetrahydro-2H-pyridazino[3′,4′:5,6][1,2,4]triazino-[4,3-b][1,2,4,5]tetrazine4. A mixture of compound 2 (0.25 g, 0.001 mol) and triethyl orthoformate (3 mL) in DMF (10 mL) was refluxed for 4 h. The mixture was poured onto ice/water (40 mL).The solid, therefore, separated and was filtered. Then, it was crystallized from ethanol to give 4 as orange powder. Yield, (62%), m.p.: 269–271 °C. IR: 3269–3192 cm−1 (4NH), 1625 cm−1 (C=N). 1H-NMR (DMSO-d6): δ = 1.21 (t, 3H, J = 7.8, CH3), 3.41 (q, 2H, J = 12.8, CH2), 6.63 (s, 1H, pyridazine CH), 7.10 (dd appears t, 1H, J = 9.6, 7.2 Hz, thiophene-HC4), 7.33 (d, 1H, J = 9.6 Hz, thiophene-HC3), 7.57 (d, 1H, J = 10.2 Hz, thiophene-HC5), 9.14 (s, 1H, NH), 11.02 (s, 1H, NH), 11.21 (s, 1H, NH), 12.02 (s, 1H, NH).13C-NMR (DMSO-d6): δ = 25.18, 32.53 (CH3 and CH2), 116.8, 118.2, 123.5, 128.6, 129.0, 131.5, 138.5, 141.4, 151.4 and 159.2. (Ar-C, C=C, C-O, C-S and C=N). Anal. Calcd. for C12H14N8OS(318.36): C, 45.27; H, 4.43; N, 35.20; S, 10.07; Found: C, 45.22; H, 4.32; N, 35.05; S, 9.89. LCMS (ESI) m/z (int. %) (319 (0.15)) [M + H]+; Calcd. For (318.35): 318 (0.22), 260 (32.53), 252 (9.59), 162 (11.68), 145 (14.28), 136 (30.06), 135 (100), 121 (36.05), 109 (20.45), 108 (20.59), 97 (42.65), 91 (18.17), 69 (36.00), 63 (16.30), 60 (22.45).
8-Amino-3-(2-thienyl)pyrazolo[5,1-c]pyridazino[3,4-e][1,2,4]triazine-7-carbonitrile5. Malononitrile (0.06 g, 0.001 mol) and triethylamine were added to a solution of compound 2 (0.25 g, 0.001 mol) in ethanol (20 mL) and the mixture was refluxed for 8 h. After cooling, the orange precipitate formed was filtered and crystallized from dioxane to give compound 5. Yield, 63%, m.p.: over 300 °C. IR: 3382 cm−1 (NH2), 2210 cm−1 (CN), 162,219 cm−1 (C=N). 1H-NMR (DMSO-d6): δ = 6.51 (s, 2H, NH2), 7.05 (dd appears t, 1H, J = 7.2, 7.2 Hz, thiophene-HC4), 7.39 (d, 1H, J = 7.6 Hz, thiophene-HC3), 7.47 (d, 1H, J = 10.2 Hz, thiophene-HC5). 13C-NMR (DMSO-d6): δ = 106.8 (CN), 116.8, 120.4, 122.5, 128.6, 129.9, 133.2, 139.4, 144.1, 151.2, 153.4 and 158.3. (Ar-C, C=C, C-S and C=N). Anal. Calcd. for C12H6N8S(294.29): C, 48.97; H, 2.05; N, 38.08; S, 10.90; Found: C, 48.72; H, 1.91; N, 37.88; S, 10.68. LCMS (ESI) m/z (int. %) (295 (0.87)) [M + H]+; Calcd. For (294.29): 294 (1.57), 253 (14.84), 252 (69.11), 251 (72.55), 250 (47.80), 249 (100), 162 (14.83), 145 (13.48), 136 (33.17), 135 (54.51), 121 (2.98), 109 (14.47), 108 (8.53), 97 (26.33), 77 (17.76), 69 (19.04), 63 (9.66), 60 (8.58).
9-Amino-3-(2-thienyl)-7,10-dihydro-2H-pyridazino[3′,4′:5,6][1,2,4]triazino[4,3-b][1,2,4,5]tetrazine6. A mixture of compound 2 (0.25 g, 0.001 mol) and thiourea (0.076 g, 0.001 mol) was refluxed in glacial acetic acid (10 mL) containing HCl (1 mL) as a catalyst for 3 h. After cooling, the mixture was poured onto ice-water and neutralized with ammonia solution. The solid, therefore, separated and was filtered and crystallized from methanol to give yellow crystals. Yield, 61% m.p.: over 300 °C. IR: 3382–3236 cm−1 (NH2, 3NH) and 1622 cm−1 (C=N). 1H-NMR (DMSO-d6): δ = 5.68 (s, 2H, NH2), 6.77 (s, 1H, pyridazine CH), 7.09 (dd appears t, 1H, J = 7.2, 7.2 Hz, thiophene-HC4), 7.33 (d, 1H, J = 7.6 Hz, thiophene-HC3), 7.48 (d, 1H, J = 10.2 Hz, thiophene-HC5), 9.82 (s, 1H, NH), 11.37 (s, 1H, NH), 13.05 (s, 1H, NH). 13C-NMR (DMSO-d6): δ = 118.2, 127.6, 128.3, 128.5, 129.4, 141.0, 141.1, 148.0, 152.3 and 158.3. (Ar-C, C=C, C-S and C=N). Anal. Calcd. for C10H9N9S(287.30): C, 41.80; H, 3.16; N, 43.88; S, 11.16; Found: C, 41.74; H, 3.09; N, 43.81; S, 11.03. LCMS (ESI) m/z (int. %) (288 (0.24)) [M + H]+; Calcd. For (287.30): 287 (0.39), 253 (20.26), 252 (89.92), 251 (100), 193 (10.10), 162 (14.59), 145 (20.58), 136 (26.98), 135 (40.27), 143 (23.34), 121 (52.87), 109 (22.51), 108 (16.18), 97 (16.05), 77 (31.66), 69 (33.64), 63 (18.45), 60 (39.19).
7-Amino-3-(2-thienyl)-2,7,9,10-tetrahydro-8H-pyridazino[3,4-e][1,2,4]triazino[3,2-c][1,2,4]triazin-8-one7. Thioglycolic acid (0.092 g, 0.07 mL, 0.001 mol) and compound 2 (0.25 g, 0.001 mol) in EtOH (15 mL) were refluxed for 6 h. After cooling, the solution was poured onto cold water. The solid formed was filtered and crystallized from ethanol to give yellowish orange crystals. Yield, 52% m.p.: over 300 °C. IR: 3366–3247 cm−1 (NH2, 2NH), 1654 cm−1 (C=O) and 1624 cm−1 (C=N). 1H-NMR (DMSO-d6): δ = 3.65, 3.89 (dd, 2H, CH2), 5.69 (s, 2H, NH2), 6.50 (s, 1H, pyridazine CH), 7.05 (dd appears t, 1H, J = 7.2, 7.2 Hz, thiophene-HC4), 7.31 (d, 1H, J = 7.6 Hz, thiophene-HC3), 7.47 (d, 1H, J = 10.2 Hz, thiophene-HC5), 9.65 (s, 1H, NH), 11.17 (s, 1H, NH).13C-NMR (DMSO-d6): δ = 118.9, 127.2, 128.4, 128.8, 129.0, 141.4, 141.8, 147.9, 151.7, 153.6 and 161.3. (Ar-C, C=C, C=O, C-S and C=N). Anal. Calcd. for C11H10N8OS(302.32): C, 43.70; H, 3.33; N, 37.07; S, 10.61; Found: C, 43.55; H, 3.21; N, 36.91; S, 10.52.
3-(2-Thienyl)-7,8-dihydro-2H-pyridazino[3′,4′:5,6][1,2,4]triazino[4,3-b][1,2,4,5]tetrazine8. A mixture of 2 (0.25 g, 0.001 mol) and formamide (3 mL) in dimethylformamide (15 mL) was refluxed for 3 h. The reaction mixture cooled and was then poured onto cold water (30 mL). The solid formed was filtered and crystallized from DMF to give 8 as a brownish powder. Yield, (58%), m.p.: over 300 °C. IR: 3255–3185 cm−1 (3NH), 1618 cm−1 (C=N). 1H-NMR (DMSO-d6): δ = 6.58 (s, 1H, pyridazine CH), 7.05 (dd appears t, 1H, J = 7.2, 7.2 Hz, thiophene-HC4), 7.02 (s, 1H, tetrazine CH), 7.33 (d, 1H, J = 7.6 Hz, thiophene-HC3), 7.48 (d, 1H, J = 10.2 Hz, thiophene-HC5), 9.85 (s, 1H, NH), 11.34 (s, 1H, NH), 11.68 (s, 1H, NH). 13C-NMR (DMSO-d6): δ = 118.9, 127.2, 128.4, 128.8, 129.0, 141.4, 141.8, 147.9, 151.7, 153.6 and 161.3. (Ar-C, C=C, C=O, C-S and C=N). Anal. Calcd. for C10H8N8S (272.29): C, 44.11; H, 2.96; N, 41.15; S, 11.78; Found: C, 44.02; H, 2.88; N, 41.13; S, 11.68.
3-(2-Thienyl)-7,8,9,10-tetrahydro-2H-pyridazino[3′,4′:5,6][1,2,4]triazino[4,3-b]-[1,2,4,5]tetrazine9. A mixture of acetic formic anhydride [32] and compound 2 (1:1, 0.001 mole) in ethanol were refluxed for 5 h. The mixture was poured onto ice water (35 mL). The precipitate formed crystallized from ethanol after filtration and drying to give compound 9 as a yellow powder. Yield, (58%), m.p.: 293–295 °C. IR: 3274–3191 cm−1 (4NH), 1625 cm−1 (C=N). 1H-NMR (DMSO-d6): δ = 3.65 (s, 2H, tetrazine CH2), 6.51 (s, 1H, pyridazine CH), 7.05 (dd appears t, 1H, J = 7.8, 7.2 Hz, thiophene-HC4), 7.30 (d, 1H, J = 6.6 Hz, thiophene-HC3), 7.45 (d, 1H, J = 9.6 Hz, thiophene-HC5), 9.85 (s, 1H, NH), 11.34 (s, 1H, NH), 11.61 (s, 1H, NH), 11.68 (s, 1H, NH). 13C-NMR (DMSO-d6): δ = 55.29 (CH2), 119.2, 123.2, 128.8, 129.5, 141.1, 148.8, 151.6, 155.6 and 156.1. (Ar-C, C=C, C-S and C=N). Anal. Calcd. for C10H10N8S(274.31): C, 43.79; H, 3.67; N, 40.85; S, 11.69; Found: C, 43.64; H, 3.59; N, 40.79; S, 11.61.
9,9′-Octane-1,8-diylbis[3-(2-thienyl)-7,8-dihydro-2H-pyridazino[3′,4′:5,6][1,2,4]triazino[4,3-b][1,2,4,5]tetrazine10. A mixture of 2 (0.25 g, 0.001 mol) and sebacoyl chloride (0.24 g, 0.21 mL, 1 mmol) and TEA (catalytic amount) in DMF (15 mL) was refluxed for 4 h. The mixture was cooled and poured onto cold ice-water. The solid formed was filtered and then crystallized from ethanol to give compound 10 as yellow crystals. Yield 87%, m.p. 294–296 °C. IR: 3292–3264 cm−1 (3NH), 1624 cm−1 (C=N). 1H-NMR (DMSO-d6): δ = 1.35 (m, 4H, 2CH2), 1.54 (m, 4H, 2CH2), 1.60 (m, 4H, 2CH2), 2.67 (t, 4H, CH2), 3.65 (s, 2H, tetrazine CH2),5.92 (s, 2H, pyridazine CH), 7.03 (dd appears t, 2H, J = 7.8, 7.2 Hz, thiophene-HC4), 7.35 (d, 2H, J = 6.6 Hz, thiophene-HC3), 7.41 (d, 2H, J = 9.6 Hz, thiophene-HC5), 9.82 (s, 2H, NH), 11.30 (s, 2H, NH), 11.69 (s, 2H, NH). 13C-NMR (DMSO-d6): δ = 23.68, 25.12, 29.50, 31.22 (4 CH2), 110.2, 120.2, 125.3, 129.9, 147.9, 152.5, 155.6, 156.7, 158.3 and 158.9. (Ar-C, C=C, C-S and C=N). Anal. Calcd. for C28H30N16S2(654.77): C, 51.36; H, 4.62; N, 34.23; S, 9.79; Found: C, 51.19; H, 4.51; N, 34.09; S, 9.65.
9-Amino-3-(2-thienyl)-2H,8H-pyridazino[3′,4′:5,6][1,2,4]triazino[3,4-b][1,3,4]thiadiazine-8-carbonitrile12. To a solution of compound 11 (3.16 g, 0.01 mol) in ethanol (25 mL), Hydrazine hydrate (10 mL, excess) was added and the reaction mixture was refluxed for 9 h. The pale yellow precipitate formed after cooling was filtered and crystallized from ethanol to give red crystals of compound 12. Yield, 92%, m.p.: over 300 °C. IR: 3317–3109 cm−1 (NH2 and NH), 2208 cm−1 (C≡N) cm−1 and 1623 cm−1 (C=N). 1H-NMR (DMSO-d6): 3.63 (s, 1H, thiadiazine CH), 5.88 (s, 1H, pyridazine CH), 6.02 (s, 1H, NH2), 7.05 (dd appears t, 1H, J = 7.8, 7.2 Hz, thiophene-HC4), 7.33 (d, 1H, J = 6.6 Hz, thiophene-HC3), 7.43 (d, 1H, J = 9.6 Hz, thiophene-HC5), 9.90 (s, 1H, NH). 13C-NMR (DMSO-d6): δ = 44.20 (thiadiazine CH), 105.2 (pyridazine CH), 115.2 (CN), 120.5, 125.2, 129.9, 151.9, 152.5, 159.1, 160.7, 162.3 and 163.9. (Ar-C, C=C, C-S and C=N). Anal. Calcd. for C12H8N8S2(328.38): C, 43.89; H, 2.46; N, 34.12; S, 19.53; Found: C, 43.74; H, 2.40; N, 34.02; S, 19.44.
N-[8-Cyano-3-(2-thienyl)-2H,8H-pyridazino[3′,4′:5,6][1,2,4]triazino[3,4-b][1,3,4]thiadiazin-9-yl]guanidine13. A mixture of compound 11 (0.328 g, 0.001 mol) and cyanamide (0.042 g, 0.001 mol) in ethanol (20 mL) and water (5 mL) was stirred under reflux for 1 h. The mixture then cooled and the solid formed was filtered and washed with 10 mL of ethanol, which resulted in a reddish brown precipitate that crystallized from methanol to give reddish orange crystals. Yield 65%, m.p. 278–280 °C. IR: 3354–3213 cm−1 (NH2 and 3NH), 2201 cm−1 (C≡N) and 1619 cm−1 (C=N amide). 1H-NMR (DMSO-d6): δ = 3.53 (s, 1H, thiadiazine CH), 5.69 (s, 1H, C=NH), 5.91 (s, 1H, pyridazine CH), 5.97 (s, 1H, C-NH-C), 6.62 (s, 2H, NH2), 7.03 (dd appears t, 1H, J = 7.2, 7.2 Hz, thiophene-HC4), 7.34 (d, 1H, J = 7.2 Hz, thiophene-HC3), 7.45 (d, 1H, J = 10.2 Hz, thiophene-HC5), 9.85 (s, 1H, NH). 13C-NMR (DMSO-d6): δ = 44.20 (S-CH-CN), 102.0 (pyridazine C), 107.4 (CN), 120.8, 125.0, 129.0, 141.3, 150.2, 151.7, 155.3, 157.2, 159.8 and 162.4 (C≡N, Ar-C, C-S and C=N). Anal. Calcd. for C13H10N10S2(370.42): C, 42.15; H, 2.72; N, 37.81; S, 17.31; Found: C, 42.03; H, 2.62; N, 37.74; S, 17.22. LCMS (ESI) m/z (int. %) (371 (4.58)) [M + H]+; Calcd. For (370.42): 370 (15.01), 304 (1.29), 300 (5.57), 239 (35.03), 230 (100), 202 (20.51), 168 (14.41), 134 (12.37), 134 (15.99), 108 (64.65), 98 (63.21), 82 (23.74), 69 (42.40), 68 (15.00), 63 (14.24).
8,10-Diamino-3-(2-thienyl)-2H,7aH-pyridazino[3′,4′:5,6][1,2,4]triazino[3,4-b]pyrimido[4,5-e][1,3,4]thiadiazine14. A mixture of 12 (0.328 g, 0.001 mol) and thiourea and/or urea (0.001 mol) was refluxed in AcOH glacial (20 mL) containing a catalytic amount of HCl (1 mL) for 4 h. The mixture left to cool was then poured onto ice-cold water and the pH adjusted to 7 with ammonia solution. The solid formed was filtered and crystallized from ethanol to give orange-red crystals. Yield, 66% for urea and 84% for thiourea, m.p.: over 300 °C. IR: 3913–3261 cm−1 (2NH2 and NH) and 1622 cm−1 (C=N). 1H-NMR (DMSO-d6): δ = 5.52 (s, 2H, NH2), 6.59 (s, 2H, NH2), 7.03 (dd appears t, 1H, J = 7.2, 7.2 Hz, thiophene-HC4), 7.31 (d, 1H, J = 7.2 Hz, thiophene-HC3), 7.41 (d, 1H, J = 10.2 Hz, thiophene-HC5), 9.94 (s, 1H, NH). 13C-NMR (DMSO-d6): δ = 45.20 (S-CH-CN), 103.0 (pyridazine C), 117.9, 120.6, 121.7, 125.7, 133.1, 137.4, 147.9, 151.0, 152.4, 158.8 and 161.8 (Ar-C, C-S and C=N). Anal. Calcd. for C13H10N10S 2(370.42): C, 42.15; H, 2.72; N, 37.81; S, 17.31; Found: C, 42.08; H, 2.68; N, 37.71; S, 17.30.
[7,7-Diamino-3-(2-thienyl)-7,8-dihydro-2H-pyridazino[3,4-e][1,2,4]triazino[6,1-c]-[1,2,4]triazin-9-yl](thioxo)acetonitrile15. A mixture of compound 12 (0.328 g, 0.001 mol) and cyanamide (0.042 g, 0.001 mol) in ethanol (20 mL) and water (5 mL) was stirred under reflux for 4 h. The mixture then cooled and the solid formed was filtered and washed with 10 mL of ethanol, which resulted in a brownish precipitate that crystallized from methanol to give reddish brown crystals. Yield 42%, m.p. 298–300 °C. IR: 3376–3212 cm−1 (2NH2 and 2NH), 2207 cm−1 (C≡N), 1619 cm−1 (C=N amide) and 1345 cm−1 (C=S amide). 1H-NMR (DMSO-d6): δ = 3.53 (s, 1H, thiadiazine CH), 5.91 (s, 1H, pyridazine CH), 6.62 (s, 4H, 2NH2), 7.03 (dd appears t, 1H, J = 7.8, 7.2 Hz, thiophene-HC4), 7.33 (d, 1H, J = 7.2 Hz, thiophene-HC3), 7.45 (d, 1H, J = 9.6 Hz, thiophene-HC5), 9.91 (s, 1H, NH), 10.63 (s, 1H, NH). 13C-NMR (DMSO-d6): δ = 101.5 (pyridazine C), 106.1 (CN), 118.3, 120.5, 125.5, 129.9, 147.2, 151.7, 152.4, 155.0, 162.2, 165.8 and 172.4 (C≡N, Ar-C, C-S, C=S and C=N). Anal. Calcd. for C13H10N10S2 (370.42): C, 42.15; H, 2.72; N, 37.81; S, 17.31; Found: C, 42.07; H, 2.68; N, 37.77; S, 17.30.
[8-Cyano-3-(2-thienyl)-2H,8H-pyridazino[3′,4′:5,6][1,2,4]triazino[3,4-b][1,3,4]thiadiazin-9-yl]carbamodithioic acid16. A mixture of compound 12 (0.328 g, 0.001 mol), carbon disulfide (1.0 mL, excess) and KOH (0.06 g, 0.01 mol) in ethanol(25mL)was heated under reflux 4 h. After cooling, the solution was poured onto ice water then acidified with dilute HCl. The red precipitate obtained was filtered, dried, and crystallized from ethanol to give red crystals. Yield, 73%, m.p.: over 300 °C. IR: 3287–3254 cm−1 (2NH), 2613 cm−1 (SH), 2201 cm−1 (CN), 1622 cm−1 (C=N) and 1345 cm−1 (C=S). 1H-NMR (DMSO-d6): δ = 3.58 (s, 1H, thiadiazine CH), 5.67 (s, 1H, pyridazine CH),7.03 (dd appears t, 1H, J = 7.8, 7.2 Hz, thiophene-HC4), 7.31 (d, 1H, J = 7.2 Hz, thiophene-HC3), 7.41 (d, 1H, J = 9.6 Hz, thiophene-HC5), 9.91 (s, 1H, NH), 10.03 (s, 1H, NH), 13.78 (s, 1H, SH).13C-NMR (DMSO-d6): δ = 47.20 (S-CH-CN), 101.5 (pyridazine C), 108.1 (CN), 120.5, 125.1, 129.9, 150.2, 152.7, 157.4, 159.0, 164.3, 165.1 and 174.1 (C≡N, Ar-C, C-S, C=S and C=N). Anal. Calcd. for C13H8N8S4 (404.52): C, 38.60; H, 1.99; N, 27.70; S, 31.71; Found: C, 38.44; H, 1.91; N, 27.56; S, 31.60.
3-(2-Thienyl)-2H,7aH-pyridazino[3′,4′:5,6][1,2,4]triazino[3,4-b]pyrimido[4,5-e][1,3,4]thiadiazine-8,10(9H,11H)dithione17. Method A: A solution of compound 16 (0.404 g, 0.001 mol) in 25 mL ethanolic sodium ethoxide (0.07 g, 0.001 mol) was refluxed for 10 h. After cooling, the solution was poured onto ice-water and acidified with HCl. The orange solid formed was filtered and then crystallized from DMF to give compound 17. Yield, 75%, m.p.: over 300 °C. Method B: Compound 12 (0.328 g, 0.001 mol) and CS2 (2 mL) in dry pyridine (10 mL) was refluxed for 13 h. After cooling, the solution was poured onto ice-water and then acidified with HCl. The obtained solid product was collected by filtration and then crystallized from DMF to give 17. Yield 61%, m.p. over 300 °C. IR: 3312–3247 cm1 (3NH), 1623 cm−1 (C=N) and 1351–1321 cm−1 (2C=S). 1H-NMR (DMSO-d6): 4.01 (s, 1H, thiadiazine CH), 5.68 (s, 1H, pyridazine CH),7.05 (dd appears t, 1H, J = 7.8, 7.2 Hz, thiophene-HC4), 7.35 (d, 1H, J = 7.2 Hz, thiophene-HC3), 7.44 (d, 1H, J = 9.6 Hz, thiophene-HC5), 9.88 (s, 1H, NH), 10.78 (s, 1H, NH), 11.08 (s, 1H, NH). 13C-NMR (DMSO-d6): δ = 47.20 (S-CH-CN), 100.1 (pyridazine C), 108.1 (CN), 120.5, 125.1, 129.9, 150.2, 152.7, 163.4, 165.0, 166.2, 172.1 and 174.1 (C≡N, Ar-C, C-S, C=S and C=N). Anal. Calcd. for C13H8N8S4(404.52): C, 38.60; H, 1.99; N, 27.70; S, 31.71; Found: C, 38.51; H, 1.93; N, 27.60; S, 31.66.
8-Amino-3-(2-thienyl)-2H,7aH-pyridazino[3′,4′:5,6][1,2,4]triazino[3,4-b]pyrimido[4,5-e][1,3,4]thiadiazine18. Compound 12 (0.328 g, 0.001 mol) in formamide (2 mL) and DMF (12 mL) was refluxed for 3 h. After cooling, reddish brown solid formed. This solid was collected by filtration and crystallized from ethanol. Yield, 45%, m.p.: over 300 °C. IR: 3368–3271 cm−1 (NH2 and NH), 1624 cm−1 (C=N). 1H-NMR (DMSO-d6): δ = 3.33 (s, 1H, thiadiazine CH), 5.62 (s, 1H, pyridazine CH), 6.52 (s, 2H, NH2), 7.03 (dd appears t, 1H, J = 7.2, 7.2 Hz, thiophene-HC4), 7.31 (d, 1H, J = 7.2 Hz, thiophene-HC3), 7.41 (d, 1H, J = 10.2 Hz, thiophene-HC5), 9.94 (s, 1H, NH).13C-NMR (DMSO-d6): δ = 40.20 (S-CH-CN), 101.0 (pyridazine C), 119.9, 120.0, 121.7, 125.7, 136.1, 151.9, 152.1, 156.3, 158.8, 160.2 and 161.8 (Ar-C, C-S and C=N). Anal. Calcd. for C13H9N9S2(355.40): C, 43.93; H, 2.55; N, 35.47; S, 18.04; Found: C, 43.77; H, 2.45; N, 35.41; S, 17.91.
Ethyl [8-cyano-3-(2-thienyl)-2H,8H-pyridazino[3′,4′:5,6][1,2,4]triazino[3,4-b][1,3,4]thiadiazin-9-yl]imidoformate19. A mixture of compound 12 (0.328 g, 0.001 mol) and triethyl orthoformate (3 mL) in DMF (10 mL) was refluxed for 2 h. After cooling the mixture poured onto ice-water (40 mL), the precipitate formed was filtered and crystallized from ethanol to give 19 as a pale yellow powder. Yield, (54%), m.p.: over 281–283 °C. IR: 3261 cm−1 (NH), 2861–2850 cm−1 (CHaliphatic), 2200 cm−1 (CN), 1625 cm−1 (C=N). 1H-NMR (DMSO-d6): δ = 1.20 (t, 3H, J = 4.2, CH3), 3.33 (q, 2H, J = 3.6, CH2), 3.41 (s, 1H, thiadiazine CH), 5.64 (s, 1H, pyridazine CH), 7.05 (dd appears t, 1H, J = 7.2, 7.2 Hz, thiophene-HC4), 7.33 (d, 1H, J = 7.2 Hz, thiophene-HC3), 7.41 (d, 1H, J = 10.2 Hz, thiophene-HC5), 9.94 (s, 1H, NH). 13C-NMR (DMSO-d6): δ = 13.7 (CH3), 40.20 (S-CH-CN), 62.59 (CH2), 102.2 (pyridazine C), 116.7, 120.0, 125.7, 129.3, 150.2, 151.9, 152.1, 156.3, 158.0, 160.8 and 161.7 (CN, Ar-C, C-S and C=N). Anal. Calcd. for C15H12N8OS2 (384.44): C, 46.86; H, 3.15; N, 29.15; S, 16.68; Found: C, 46.76; H, 3.03; N, 29.00; S, 16.49.
9-Amino-8-imino-3-(2-thienyl)-7a,8-dihydro-2H,9H-pyridazino[3′,4′:5,6][1,2,4]-triazino[3,4-b]pyrimido[4,5-e][1,3,4]thiadiazine20. A mixture of compound 19 (0.384 g, 0.001 mol) and hydrazine hydrate (4 mL (excess), 80%) in dimethylformamide (10 mL) was refluxed for 4h.Ayellow precipitate formed after cooling, which was filtered and crystallized from dimethylformamide. Yield, 71%, m.p.: over 300 °C. IR: 3381–3215 cm−1 (NH2, 2NH) and 1621 cm−1 (C=N). 1H-NMR (DMSO-d6): δ = 3.30 (s, 1H, thiadiazine CH), 5.52 (s, 1H, pyridazine CH), 6.14 (s, 2H, NH2), 7.03 (dd appears t, 1H, J = 7.2, 7.2 Hz, thiophene-HC4), 7.36 (d, 1H, J = 7.2 Hz, thiophene-HC3), 7.45 (d, 1H, J = 10.2 Hz, thiophene-HC5), 9.94 (s, 1H, NH), 10.96 (s, 1H, NH). 13C-NMR (DMSO-d6): δ = 45.61 (S-CH-CN), 100.8 (pyridazine C), 120.5, 125.7, 129.9, 144.5, 147.2, 152.5, 155.1, 157.3, 159.8, 162.2 and 163.1 (Ar-C, C-S and C=N). Anal. Calcd. for C13H10N10S2 (370.41): C, 42.15; H, 2.72; N, 37.81; S, 17.91; Found: C, 42.04; H, 2.61; N, 37.66; S, 17.73.
8,10-Diamino-3-(2-thienyl)-2H,7aH-pyridazino[3′,4′:5,6][1,2,4]triazino[3,4-b]pyrido-[2,3-e][1,3,4]thiadiazine-9-carbonitrile21. A suspension of compound 12 (0.328 g, 0.001 mol) in ethanol (25 mL) malononitrile (0.06 g, 0.001 mol) was combined with a catalytic amount of triethylamine (0.5 mL). The mixture was refluxed for 8 h. After cooling, reddish precipitate formed, which was filtered and crystallized from dioxane to give 21. Yield, 58%, m.p.: over 300 °C. IR: 3382–3261 cm−1 (2NH2 and NH), 2200 cm−1 (CN), 1618 cm−1 (C=N). 1H-NMR (DMSO-d6): δ = 3.63 (s, 1H, thiadiazine CH), 5.88 (s, 1H, pyridazine CH), 6.02 (s, 1H, NH2), 6.59 (s, 1H, NH2), 7.05 (dd appears t, 1H, J = 7.8, 7.2 Hz, thiophene-HC4), 7.33 (d, 1H, J = 6.6 Hz, thiophene-HC3), 7.43 (d, 1H, J = 9.6 Hz, thiophene-HC5), 9.90 (s, 1H, NH). 13C-NMR (DMSO-d6): δ = 37.91 (thiadiazine CH), 89.33 (pyridazine CH), 91.30, 116.2 (CN), 120.5, 125.2, 129.9, 141.3, 143.2, 151.1, 152.1, 159.6, 160.7, 161.3 and 163.9. (CN, Ar-C, C=C, C-S and C=N). Anal. Calcd. for C15H10N10S2 (394.44): C, 45.68; H, 2.56; N, 35.51; S, 16.26; Found: C, 45.54; H, 2.50; N, 35.42; S, 16.18.
8-Amino-10-oxo-3-(2-thienyl)-10,11-dihydro-2H,7aH-pyridazino[3′,4′:5,6][1,2,4]triazino[3,4-b]pyrido[2,3-e][1,3,4]thiadiazine-9-carbonitrile22. A mixture of compound 12 (0.328 g, 0.001 mol), ethyl cyanoacetate (0.113 g, 0.001 mol) with a catalytic amount of Et3N in ethanol (20 mL) was refluxed for 9 h. The resulting solid mass was filtered and crystallized from dioxane to yield compound 22 as an orange powder. Yield 61%, m.p. over 300 °C. IR: 3382–3200 cm−1 (NH2 and 2NH), 2199 cm−1 (CN), 1659 cm−1 (C=O amide) and 1624 cm−1 (C=N). 1H-NMR (DMSO-d6): δ = 3.61 (s, 1H, thiadiazine CH), 5.80 (s, 1H, pyridazine CH), 6.62 (s, 1H, NH2), 7.05 (dd appears t, 1H, J = 7.8, 7.2 Hz, thiophene-HC4), 7.31 (d, 1H, J = 6.6 Hz, thiophene-HC3), 7.45 (d, 1H, J = 9.6 Hz, thiophene-HC5), 9.90 (s, 1H, NH), 11.43 (s, 1H, NH). 13C-NMR (DMSO-d6): δ = 39.84 (thiadiazine CH), 89.03 (pyridazine CH), 94.30, 116.2 (CN), 120.5, 125.2, 129.9, 148.3, 149.2, 151.1, 153.2, 158.7, 160.7, 162.3 and 164.9. (CN, Ar-C, C=C, C-S, C=N and C=O). Anal. Calcd. for C15H9N9OS2 (395.42): C, 45.56; H, 2.29; N, 31.88; S, 16.22; Found: C, 45.38; H, 2.18; N, 31.71; S, 16.11.
[8-Oxo-3-(2-thienyl)-8,9-dihydro-2H,7aH-pyridazino[3′,4′:5,6][1,2,4]triazino[3,4-b]pyrimido[4,5-e][1,3,4]thiadiazin-10-yl]acetonitrile23. Compound 12 (0.328 g, 0.001 mol) with ethyl cyanoacetate (10 mL) was refluxed for 5 h. The solid formed was filtered and then crystallized from dioxane to give compound 23. Yield 59%, m.p. over 300 °C. IR: 3259–3221 cm−1 (2NH), 2200 cm−1 (CN), 1668 cm−1 (C=O amide) and 1623 cm−1 (C=N). 1H-NMR (DMSO-d6): δ = 3.23 (s, 2H, CH2CN), 3.66 (s, 1H, thiadiazine CH), 5.67 (s, 1H, pyridazine CH), 7.04 (dd appears t, 1H, J = 7.8, 7.2 Hz, thiophene-HC4), 7.34 (d, 1H, J = 6.6 Hz, thiophene-HC3), 7.40 (d, 1H, J = 9.6 Hz, thiophene-HC5), 9.82 (s, 1H, NH), 10.56 (s, 1H, NH). 13C-NMR (DMSO-d6): δ = 22.83 (CH2), 45.23 (thiadiazine CH), 84.03 (pyridazine CH), 120.5 (CN), 122.0, 125.2, 129.4, 149.2, 152.1, 153.2, 157.2, 161.7, 163.3, 164.3 and 166.1. (CN, Ar-C, C=C, C-S, C=N and C=O). Anal. Calcd. for C15H9N9OS2 (395.42): C, 45.56; H, 2.29; N, 31.88; S, 16.22; Found: C, 45.41; H, 2.23; N, 31.74; S, 16.06.
N-[8-Cyano-3-(2-thienyl)-2H,8H-pyridazino[3′,4′:5,6][1,2,4]triazino[3,4-b][1,3,4]thiadiazin-9-yl]acetamide24. A solution of compound 12 (0.328 g, 0.001 mol) in acetic anhydride (10 mL) was refluxed for 6 h. The reaction mixture was poured onto ice-water and the resulting solid was filtered and crystallized from ethanol to give 24 as yellow crystals. Yield 69%, m.p. 284–286 °C. IR: 3244–3232 cm−1 (2NH), 2199 cm−1 (CN), 1660 cm−1 (C=O amide) and 1622 cm−1 (C=N). 1H-NMR (DMSO-d6): δ = 1.99 (s, 3H, CH3), 3.65 (s, 1H, thiadiazine CH), 5.71 (s, 1H, pyridazine CH), 7.04 (dd appears t, 1H, J = 7.8, 7.2 Hz, thiophene-HC4), 7.33 (d, 1H, J = 6.6 Hz, thiophene-HC3), 7.42 (d, 1H, J = 9.6 Hz, thiophene-HC5), 9.91 (s, 1H, NH), 11.56 (s, 1H, NH). 13C-NMR (DMSO-d6): δ = 25.23 (CH2), 41.30 (thiadiazine CH), 91.27 (pyridazine CH), 114.6, 120.5 (CN), 125.1, 129.5, 137.2, 144.5, 149.1, 150.1, 151.2, 154.2 and 162.1. (CN, Ar-C, C=C, C-S, C=N and C=O). Anal. Calcd. for C14H10N8OS2(370.41): C, 45.40; H, 2.72; N, 30.25; S, 17.31; Found: C, 45.28; H, 2.65; N, 30.21; S, 17.20.

3.2. Anti-Tumor Activity Assay

Methods

The tested human carcinoma cell lines were obtained from the American Type Culture Collection (ATCC, Rockville, MD, USA). The cells were grown on RPMI-1640 medium supplemented with 10% heat-inactivated fetal calf serum, 1% l-glutamine, and 50 µg/mL gentamycin at 37 °C in a humidified atmosphere with a 5% CO2 incubator (Shel lab 2406, Candler, NC, USA).
For anti-tumor assays, the tumor cell lines were suspended in medium at concentration 5 × 104 cell/well in Corning® 96-well tissue culture plates and then incubated for 24 h. The tested compounds were then added into 96-well plates (three replicates) to achieve ten concentrations for each compound (started from 500 to 1 µg/mL). Six vehicle controls with media or 0.1% DMSO were run for each 96-well plate as a control. After incubating for 24 h, the numbers of viable cells were determined by the MTT assay [33]. Briefly, the media was removed from the 96-well plate and replaced with 100 µL of fresh culture RPMI 1640 medium without phenol red. Then, 10 µL of the 12 mM MTT (3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide (Sigma, Taufkirchen, Germany) was added to each well including the untreated controls. The 96-well plates were then incubated at 37 °C and 5% CO2 for 4 h. An 85 µL aliquot of the media was removed from the wells and 50 µL of DMSO was added to each well and mixed thoroughly with the pipette and incubated at 37 °C for 10 min. Then, the optical density was measured at 590 nm with the microplate reader (SunRise, TECAN, Mannedorf, Switzerland)) to determine the number of viable cells and the percentage of viability was calculated as [(ODt/ODc)] × 100% where ODt is the mean optical density of wells treated with the tested sample and ODc is the mean optical density of untreated cells. The relation between surviving cells and drug concentration is plotted to obtain the survival curve of each tumor cell line after treatment with the specified compound. The 50% inhibitory concentration (IC50), which is the concentration required to cause toxic effects in 50% of intact cells, was estimated from graphic plots of the dose–response curve for each concentration using Graphpad Prism software (San Diego, CA, USA) [34].

4. Conclusions

Novel derivatives of fused 1,2,4-triazines were obtained via subsequent reaction methodology. The new synthesized compounds were screened against three cell lines, HepG2, HCT-116 and MCF-7, to discover their anti-cancer activity. The results revealed that all the tested compounds showed inhibitory activity against the tumor cell lines in a concentration-dependent manner. We plan to evaluate the affinity and selectivity of these and other related synthetic compounds towards adenosine receptor subtypes A2A and A3. The results will be used to optimize these structures for biological activity and our conclusions will be reported in a future publication.

Acknowledgments

This work was supported by grants from Vice President for Graduate Study and Research, Taif University, Saudi Arabia under project grants No. 1-438-5765.

Author Contributions

Rania S. Ali performed the experiments; Rania S. Ali analyzed the data; Hosam A. Saad Contributed reagents/materials/analysis tools; Rania S. Ali wrote the paper.

Conflicts of Interest

The authors declare no conflict of interest.

References

  1. Patel, A.; Mehta, G.A. Synthesis and characterization of some pyrimidine-quinoline clubbed molecules and their microbicidal efficacy. J. Saudi Chem. Soc. 2010, 14, 203–208. [Google Scholar] [CrossRef]
  2. Molvi, K.I.; Mansuri, M.; Sudarsanam, V.; Patel, M.M.; Andrabi, S.M.; Haque, N. Synthesis, anti-inflammatory, analgesic and antioxidant activities of some tetrasubstituted thiophenes. J. Enzyme Inhib. Med. Chem. 2008, 23, 829–838. [Google Scholar] [CrossRef] [PubMed]
  3. Gouda, M.A.; Eldien, H.F.; Girges, M.M.; Berghot, M.A. Synthesis and antitumor evaluation of thiophene-based azo dyes incorporating pyrazolone moiety. J. Saudi Chem. Soc. 2016, 20, 151–157. [Google Scholar] [CrossRef]
  4. Desai, N.C.; Dodiya, A.M.; Rajpara, K.M.; Rupala, Y.M. Synthesis and antimicrobial screening of 1,3,4-oxadiazole and clubbed thiophene derivatives. J. Saudi Chem. Soc. 2014, 18, 255–261. [Google Scholar] [CrossRef]
  5. Deep, A.; Narasimhan, B.; Aggarwal, S.; Kaushik, D.; Arun, K.S. Thiophene scaffold as prospective central nervous system agent: A review. Cent. Nerv. Syst. Agents Med. Chem. 2016, 16, 58–64. [Google Scholar] [CrossRef]
  6. Fathima, N.; Ziaulla, M.; Banu, A.; Panchamukhi, S.I.; Khazi, I.A.; Begum, N.S. Synthesis, spectroscopy and X-ray crystal structure of 9-methyl-3-thiophen-2-yl-thieno[3,2-e][1,2,4]triazolo[4,3-c]pyrimidine-8-carboxylic acid ethyl ester. Am. J. Anal. Chem. 2011, 2, 371–375. [Google Scholar] [CrossRef]
  7. Pulipati, L.; Yogeeswari, P.; Sriram, D.; Kantevari, S. Click-based synthesis and antitubercular evaluation of novel dibenzo[b,d]thiophene-1,2,3-triazoles with piperidine, piperazine, morpholine and thiomorpholine appendages. Bioorg. Med. Chem. Lett. 2016, 26, 2649–2654. [Google Scholar] [CrossRef] [PubMed]
  8. Wang, X.; Zhu, L.; Chen, S.; Xu, X.; Au, C.T.; Qiu, R. Nickel-catalyzed direct C (sp3)–H arylation of aliphatic amides with thiophenes. Org. Lett. 2015, 17, 5228–5231. [Google Scholar] [CrossRef] [PubMed]
  9. Benachenhou, F.; Mesli, A.; Guilard, R. Synthesis of Schiff bases by aromatic amine condensation with 3,3′-bithiophenes-2,2′ and 4,4′-dicarbaldehydes. Arabian J. Chem. 2013, 6, 313–317. [Google Scholar] [CrossRef]
  10. Rani, M.; Mohamad, Y. Synthesis, studies and in vitro antibacterial activity of some 5-(thiophene-2-yl)-phenyl pyrazoline derivatives. J. Saudi Chem. Soc. 2014, 18, 411–417. [Google Scholar] [CrossRef]
  11. Baert, F.; Cabanetos, C.; Allain, M.; Silvestre, V.; Leriche, P.; Blanchard, P. Thieno[2,3-b]indole-based small push-pull chromophores: Synthesis, structure, and electronic properties. Org. Lett. 2016, 18, 1582–1585. [Google Scholar] [CrossRef] [PubMed]
  12. Gopi, C.; Dhanaraju, M.D. Synthesis, spectroscopy characterization and biological activities of some novel 1-(3-(N,N-dimethylamino)-1-(5-substituted thiophene-2-yl)propylidene semicarbazone Mannich base derivatives. Beni-Suef Univ. J. Basic Appl. Sci. 2018. [Google Scholar] [CrossRef]
  13. Sztanke, K.; Pasternak, K.; Sztanke, M.; Kandefer-Szerszen, M.; Kozioł, A.E.; Dybała, I. Crystal structure, antitumour and antimetastatic activities of disubstituted fused 1,2,4-triazinones. Bioorg. Med. Chem. Lett. 2009, 19, 5095–5100. [Google Scholar] [CrossRef] [PubMed]
  14. Sztanke, K.; Pasternak, K.; Rajtar, B.; Sztanke, M.; Majek, M.; Polz-Dacewicz, M. Identification of antibacterial and antiviral activities of novel fused 1,2,4-triazine esters. Bioorg. Med. Chem. 2007, 15, 5480–5486. [Google Scholar] [CrossRef] [PubMed]
  15. Sztanke, K.; Pasternak, K.; Rzymowska, J.; Sztanke, M.; Kandefer-Szerszeń, M.; Dybała, I.; Kozioł, A.E. Identification of antitumor activity of novel derivatives of 8-aryl-2,6,7,8-tetrahydroimidazo[2,1-c][1,2,4]triazine-3,4-dione and 8-aryl-4-imino-2,3,7,8-tetrahydroimidazo[2,1-c][1,2,4]triazin-3(6H)-one. Bioorg. Med. Chem. 2007, 15, 2837–2849. [Google Scholar] [CrossRef] [PubMed]
  16. Sztanke, K.; Pasternak, K.; Rzymowska, J.; Sztanke, M.; Kandefer-Szerszeń, M. Synthesis, structure elucidation and identification of antitumoural properties of novel fused 1,2,4-triazine aryl derivatives. Eur. J. Med. Chem. 2008, 43, 1085–1094. [Google Scholar] [CrossRef] [PubMed]
  17. Sztanke, K.; Rzymowska, J.; Niemczyk, M.; Dybała, I.; Kozioł, A.E. Synthesis, crystal structure and anticancer activity of novel derivatives of ethyl 1-(4-oxo-8-aryl-4,6,7,8-tetrahydroimidazo[2,1-c][1,2,4]triazin-3-yl)formate. Eur. J. Med. Chem. 2006, 41, 539–547. [Google Scholar] [CrossRef] [PubMed]
  18. El-Gendy, Z.; Morsy, J.M.; Allimony, H.A.; Ali, W.R.; Abdel-Rahman, R.M. Synthesis of heterobicyclic nitrogen systems bearing the 1,2,4-triazine moiety as anti-HIV and anticancer drugs, part III. Pharmazie 2001, 56, 376–383. [Google Scholar] [PubMed]
  19. Abdel-Rahman, R.M.; Morsy, J.M.; El-Edfawy, S.; Amine, H.A. Synthesis of some new heterobicyclic nitrogen systems bearing the 1,2,4-triazine moiety as anti-HIV and anti-cancer drugs, Part II. Pharmazie 1999, 54, 667–671. [Google Scholar] [PubMed]
  20. Abdel-Rahman, R.M.; Morsy, J.M.; Hanafy, F.; Amene, H.A. Synthesis of heterobicyclic nitrogen systems bearing the 1,2,4-triazine moiety as anti-HIV and anticancer drugs: Part I. Pharmazie 1999, 54, 347–351. [Google Scholar] [PubMed]
  21. Ciciani, G.; Coronnello, M.; Guerrini, G.; Selleri, S.; Cantore, M.; Failli, P.; Mini, E.; Costanzo, A. Synthesis of new pyrazolo[5,1-c][1,2,4] benzotriazines, pyrazolo[5,1-c]pyrido[4,3-e][1,2,4] triazines and their open analogues as cytotoxic agents in normoxic and hypoxic conditions. Bioorg. Med. Chem. 2008, 16, 9409–9419. [Google Scholar] [CrossRef] [PubMed]
  22. Coronnello, M.; Ciciani, G.; Mini, E.; Guerrini, G.; Caciagli, B.; Costanzo, A.; Mazzei, T. Cytotoxic activity of 3-nitropyrazolo[5,1-c][1,2,4]benzotriazine derivatives: A new series of anti-proliferative agents. Anti-Cancer Drugs 2005, 16, 645–651. [Google Scholar] [CrossRef] [PubMed]
  23. Massry, A.M.; Asal, A.M.; Khattab, S.N.; Haiba, N.S.; Awney, H.A.; Helmy, M.; Langer, V.; Amer, A. Amer. Synthesis and structure elucidation of novel fused 1,2,4-triazine derivatives as potent inhibitors targeting CYP1A1 activity. Bioorg. Med. Chem. 2012, 20, 2624–2637. [Google Scholar] [CrossRef] [PubMed]
  24. Neckers, L.; Ivy, S.P. Heat shock protein 90. Curr. Opin. Oncol. 2003, 15, 419–424. [Google Scholar] [CrossRef] [PubMed]
  25. Yi, F.; Regan, L. A novel class of small molecule inhibitors of Hsp90. ACS Chem. Biol. 2008, 3, 645–654. [Google Scholar] [CrossRef] [PubMed]
  26. Haiba, M.E.; Fathalla, O.A.; Zeid, I.F.; Abdel-mohsen, M.S.; El-Moez, S.I.; El-serwy, W.S. Synthesis and evaluation of some novel tetrahydropyrimidine derivatives as antimicrobial and cytotoxic agents. Res. Chem. Intermed. 2013, 39, 3763–3774. [Google Scholar] [CrossRef]
  27. Kramer, J.B.; Showalter, H.D. Pyridotriazines and Pyridopyridazines. U.S. Patent 6,683,183, 27 January 2004. [Google Scholar]
  28. Showalter, H.D.; Turbiak, A.J.; Fearon, E.R.; Bommer, G.T. Pyrimidotriazinediones and Pyrimidopyrimidinediones and Methods of Using the Same. U.S. Patent Application No. 13,055,220, 7 July 2011. [Google Scholar]
  29. Elsayed, E.H.; Radwan, E.M. New potential antitumor nitrogen heterocycles: Synthesis and cytotoxic evaluation. Pharma Chem. 2017, 8, 399–413. [Google Scholar]
  30. Saad, H.A.; Youssef, M.M.; Mosselhi, M.A. Microwave Assisted Synthesis of Some New Fused 1,2,4-Triazines Bearing Thiophene Moieties with Expected Pharmacological Activity. Molecules 2011, 16, 4937–4957. [Google Scholar] [CrossRef] [PubMed]
  31. Saad, H.A. Synthesis of novel fused heterocyclic compounds from 7-amino-[1,2,4]triazino[3,4-b][1,3,4]thiadiazine-8-carbonitrile. Curr. Org. Synth. 2012, 9, 573–582. [Google Scholar] [CrossRef]
  32. Krimen, L.I. Acetic formic anhydride. Org. Synth. 1970, 50, 1–3. [Google Scholar]
  33. Mosmann, T. Rapid colorimetric assay for cellular growth and survival: Application to proliferation and cytotoxicity assays. J. Immunol. Methods 1983, 65, 55–63. [Google Scholar] [CrossRef]
  34. Ghorab, M.M.; Alsaid, M.S.; El-Gaby, M.S.; Safwat, N.A.; Elaasser, M.M.; Soliman, A.M. Biological evaluation of some new N-(2,6-dimethoxypyrimidinyl)thioureidobenzenesulfonamide derivatives as potential antimicrobial and anticancer agents. Eur. J. Med. Chem. 2016, 124, 299–310. [Google Scholar] [CrossRef] [PubMed]
Sample Availability: Samples of the compounds are available from the authors.
Scheme 1. Synthesis and some reactions on 3-hydrazinyl-7-(thiophen-2-yl)pyridazino[3,4-e][1,2,4]triazin-4(6H)-amine.
Scheme 1. Synthesis and some reactions on 3-hydrazinyl-7-(thiophen-2-yl)pyridazino[3,4-e][1,2,4]triazin-4(6H)-amine.
Molecules 23 01024 sch001
Scheme 2. Some reactions on 4(6H)-amino-3-hydrazinyl-7-(thiophen-2-yl)pyridazino[3,4-e][1,2,4]triazine.
Scheme 2. Some reactions on 4(6H)-amino-3-hydrazinyl-7-(thiophen-2-yl)pyridazino[3,4-e][1,2,4]triazine.
Molecules 23 01024 sch002
Scheme 3. Synthesis and some reactions of 3-amino-3-(2-thienyl)-2H,8H-pyridazino[3′,4′:5,6][1,2,4]triazino[3,4-b][1,3,4]thiadiazine-8-carbonitrile.
Scheme 3. Synthesis and some reactions of 3-amino-3-(2-thienyl)-2H,8H-pyridazino[3′,4′:5,6][1,2,4]triazino[3,4-b][1,3,4]thiadiazine-8-carbonitrile.
Molecules 23 01024 sch003
Scheme 4. The mechanism of formation of compound 15.
Scheme 4. The mechanism of formation of compound 15.
Molecules 23 01024 sch004
Scheme 5. Some reactions of 3-amino-3-(2-thienyl)-2H,8H-pyridazino[3′,4′:5,6][1,2,4]triazino[3,4-b][1,3,4]thiadiazine-8-carbonitrile.
Scheme 5. Some reactions of 3-amino-3-(2-thienyl)-2H,8H-pyridazino[3′,4′:5,6][1,2,4]triazino[3,4-b][1,3,4]thiadiazine-8-carbonitrile.
Molecules 23 01024 sch005
Scheme 6. Mechanism of cyclization of compound 16.
Scheme 6. Mechanism of cyclization of compound 16.
Molecules 23 01024 sch006
Scheme 7. Some reactions of 9-amino-3-(2-thienyl)-2H,8H-pyridazino[3′,4′:5,6][1,2,4]triazino[3,4-b][1,3,4]thiadiazine-8-carbonitrile.
Scheme 7. Some reactions of 9-amino-3-(2-thienyl)-2H,8H-pyridazino[3′,4′:5,6][1,2,4]triazino[3,4-b][1,3,4]thiadiazine-8-carbonitrile.
Molecules 23 01024 sch007
Scheme 8. Mechanism of formation of compound 22.
Scheme 8. Mechanism of formation of compound 22.
Molecules 23 01024 sch008
Scheme 9. Mechanism of formation of compound 23.
Scheme 9. Mechanism of formation of compound 23.
Molecules 23 01024 sch009
Figure 1. The anti-tumor activities of the tested compounds expressed as IC50 values and compared with reference standard drugs evaluated on breast cancer, liver cancer, and colon carcinoma cell lines.
Figure 1. The anti-tumor activities of the tested compounds expressed as IC50 values and compared with reference standard drugs evaluated on breast cancer, liver cancer, and colon carcinoma cell lines.
Molecules 23 01024 g001
Table 1. The anti-tumor activities of the tested compounds expressed as IC50 values and compared with reference standard drugs evaluated on breast cancer and liver cancer cell lines.
Table 1. The anti-tumor activities of the tested compounds expressed as IC50 values and compared with reference standard drugs evaluated on breast cancer and liver cancer cell lines.
Sample CodeMCF-7HepG-2HCT-116
229.6 ± 0.925 ± 0.430.9 ± 0.4
1243.9 ± 1.228.6 ± 0.934.9 ± 0.6
354 ± 0.835.5 ± 1.246.2 ± 0.7
454.5 ± 1.230.2 ± 0.445.4 ± 0.8
5168 ± 4.5102 ± 0.9160 ± 2.3
6100 ± 0.930.7 ± 0.759.3 ± 0.8
778.2 ± 1.235.6 ± 0.959.5 ± 1.2
10404 ± 3.4206 ± 2.3244 ± 3.9
1629.2 ± 0.723.6 ± 0.627.4 ± 0.6
Cisplatin5.71 ± 0.43.67 ± 0.22.43 ± 0.2

Share and Cite

MDPI and ACS Style

Ali, R.S.; Saad, H.A. Synthesis and Pharmacological Studies of Unprecedented Fused Pyridazino[3′,4′:5,6][1,2,4]triazino[3,4-b][1,3,4]thiadiazine Derivatives. Molecules 2018, 23, 1024. https://0-doi-org.brum.beds.ac.uk/10.3390/molecules23051024

AMA Style

Ali RS, Saad HA. Synthesis and Pharmacological Studies of Unprecedented Fused Pyridazino[3′,4′:5,6][1,2,4]triazino[3,4-b][1,3,4]thiadiazine Derivatives. Molecules. 2018; 23(5):1024. https://0-doi-org.brum.beds.ac.uk/10.3390/molecules23051024

Chicago/Turabian Style

Ali, Rania S., and Hosam A. Saad. 2018. "Synthesis and Pharmacological Studies of Unprecedented Fused Pyridazino[3′,4′:5,6][1,2,4]triazino[3,4-b][1,3,4]thiadiazine Derivatives" Molecules 23, no. 5: 1024. https://0-doi-org.brum.beds.ac.uk/10.3390/molecules23051024

Article Metrics

Back to TopTop